NVSEF News and Press, Novartis Ag Basel Akt From 06/29/23

2023-06-29 12:00:00 ET Summary Where do you put money that you need? I have some big upcoming checks to write. Here are ideas for protecting earmarked principal. Activision My Activision Blizzard, Inc. ( ATVI ) calls will be fantastic if the FTC l...

2023-06-27 17:50:30 ET Summary The primary endpoint of MoonLake Immunotherapeutics' HiSCR75 was met with statistical significance in the phase 2 MIRA trial, when Hidradenitis suppurativa patients were treated with sonelokimab. The global Hidradenitis Suppurativa market is expected...

2023-06-26 11:37:57 ET Summary WisdomTree International High Dividend Fund holds over 500 high-yield stocks from developed countries. 63% of assets is in 5 countries and 40% is in 2 sectors. Valuation is unattractive relative to one of its main competitors. The fund has lo...

2023-06-20 06:58:24 ET Summary Ionis Pharmaceuticals' phase 2 study showed that patients treated with donidalorsen through week 17 achieved a 90% reduction in hereditary angioedema attack compared to placebo; the second dose brought a 97% reduction. Clinical trial results from the...

2023-06-18 04:24:59 ET Summary SomaLogic presents with a lack of fundamental, sentimental, and valuation factors to suggest a price change. I've revised my investment thesis to hold, due to the firm's Q1 results, revenue headwinds, and a market valuation of 0.8x book value. I ...

2023-06-12 16:13:12 ET Summary Novartis announced the acquisition of Chinook Therapeutics for $3.5 billion, boosting its pipeline and expanding into the kidney disease market. The deal can be paid for with around three months' worth of Novartis' free cash generation, and the compa...

2023-06-12 13:27:35 ET Shares of clinical-stage biotechs Olema Pharmaceuticals ( NASDAQ: OLMA ) and Arvinas ( NASDAQ: ARVN ) rose on Monday as Wall Street reacted to comments from Jefferies and Oppenheimer on a class of breast cancer drugs called oral selective estrogen rece...

2023-06-08 23:21:36 ET Summary The article analyzes Amgen's financial performance, including balance sheet trends, valuation models, and competition & margin trends. We'll discuss AMGN's dividend and free cash flow of this large, very well-covered dividend growth stock. Am...

2023-06-08 17:27:08 ET Summary Today, we take our first in-depth look at a developmental concerned called Ideaya Biosciences, Inc. Ideaya Biosciences is moving forward a diverse pipeline of drug candidates based on its focus on synthetic lethality. An investment analysis follo...

2023-06-08 07:39:39 ET Summary We analyzed Novartis pipeline growth versus patent expiration. Positive adjuvant data for Kisqali could accelerate market share shifts. Novartis' equal weight rating is due to high margin sales lost to generics and risks from US healthcare reform...